Young adults with CAC>90th percentile, i.e, premature advanced atherosclerosis, have higher all-cause and cause-specific mortality. This unique phenotype should be a target for aggressive clinical prevention Michael J. Blaha Moein Dehesh Johns Hopkins Ciccarone Center academic.oup.com/eurjpc/advance…

Our Keto paper is among the top cited papers in JACC Journals (Advances): Carbohydrate Restriction-Induced Elevations in LDL-Cholesterol and Atherosclerosis: The KETO Trial | JACC: Advances jacc.org/doi/10.1016/j.…

Why waiting to start on a cholesterol-lowering medication until you are older is NOT a good strategy. Start at: Age 60 - 27% reduction in events. Age 50 - 35 reduction in events. Age 30 - 52% reduction in events. And this is with a starting LDL-C of only 3.5 (67).

2025 US guidelines for the management of ACS (STEMI and NSTE-ACS) just released. Insertion of a microaxial flow pump (Impella) to prevent death in in cardiogenic shock has received a class IIa LOE B-R recommendation. IABP and VA-ECMO are class III for rourine use.

It’s time again to introduce myself to the new friends! My name is Hooman Bakhshi, interventional cardiologist in Northern VA. I am also research faculty at Johns Hopkins SOM. I post mainly about new studies in cardiology . #CardioX follow me for the exciting news during #ACC25

An incredible session with world-class expert Dr. Michael Blaha breaking down why CAC scoring is a must-have tool in prevention. Evidence-packed. Practice-changing. #ACC25 #CAC #CVprev Michael J. Blaha

JACC STATE-OF-THE-ART REVIEW: do you have problems understanding all the new drugs to lower triglycerides and remnant cholesterol: lipid and side effects, target populations, approved or not by FDA+EMA? Ask Tybjærg Nordestgaard et al explain the details authors.elsevier.com/a/1l4pB2d9GI27…

Exercise-induced changes in miRNA expression hold significant potential for cardiovascular protection and may serve as promising biomarkers and therapeutic targets 🔗atherosclerosis-journal.com/article/S0021-… European Atherosclerosis Society

Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction AβYSS Trial (n=3698, 3.0 yrs FU): 📍β-blocker interruption led to ↑ SBP (+3.7), DBP (+3.3), HR (+10 bpm); all P < .001. 📍Effect seen in both HTN & non-HTN pts. 📍HTN pts had ↑ risk

We have a new Lp(a) paper, led by David Erlinge from PROSPECT 2 using IVUS/NIRS. It shows high Lp(a) associates most with vulnerable plaque characteristics, whereas LDL-C with plaque burden. Lp(a) was measured by our UC San Diego Cardiology assay, the only Lp(a) assay I am aware of that is

🚨 New Study Alert! 🚨 We don’t have a lot of placebo-controlled RCT investigating correlation of influenza vaccination and cardiovascular outcomes in patients with CAD. Flu shot seems needed to protect heart❤️💉 #IVCAD #CardioTwitter #PrevCardio #MedTwitter #Influenza

How much do you know about inflammatory residual risk? Despite routine use of lipid-lowering, blood pressure-lowering, & antithrombotic therapy, people with #ASCVD still face a 30% risk of a major adverse cardiovascular event over 10 years. Tourmaline Bio ow.ly/Z3Pi50VZpgY

Coronary inflammation and atherosclerosis in young adults (18–45 yrs) assessed by CCTA — new insights into early cardiovascular risk. 📖 ow.ly/L3u450VZEst Michael D. Shapiro Leandro Slipczuk Khurram Nasir Ron Blankstein #PreventiveCardiology #CVDprevention #ASPC #CardioTwitter

🫀 Hidden heart risks in young adults? A new study highlights how a coronary inflammation marker detected via CCTA can help identify early cardiovascular risk—even in people aged 18–45 with no symptoms. news-medical.net/news/20250528/… #PreventiveCardiology #CardioTwitter AJPC

Optimal medical care and coronary flow capacity-guided myocardial revascularization vs usual care for chronic coronary artery disease: the CENTURY trial. Read more in the @EHJ doi.org/10.1093/eurhea… #CENTURYTrial #MyocardialRevascularization @ESCardio European Society of Cardiology Journals

This JAMA Insights article discusses the role of lipoprotein(a) in cardiovascular disease, its genetic determinants, and potential therapeutic strategies to manage elevated levels. ja.ma/4jrWSbT

Our new JAMA Cardiology study finds that many US adults don't know that they have hypertension, diabetes, or high cholesterol Nearly 1 in 3 young adults w/ hypertension, 2 in 5 with diabetes, and 1 in 4 with high cholesterol are unaware of their condition. bit.ly/45an6MC

Antiplatelet or anticoagulant? The new ACS guideline decodes the chaos with clarity. A must-read roadmap for frontline care 🧭 jacc.org/doi/10.1016/j.… #JACC #cvACS #ClinicalGuidelines Dr Roxana Mehran David J. Cohen, MD, MSc Behnood Bikdeli Harlan Krumholz

Online—Prevalence of #clinical #obesity versus #BMI-defined obesity among US adults: a cohort study thelancet.com/journals/landi… #FREE to read

Excellent methodology and paper👌